Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GTP binding protein overexpressed in skeletal muscle (GEM) is a member of the RAD/GEM family of small GTP-binding proteins, structurally related to the Ras superfamily[1][4][5][8]. GEM is associated with the inner face of the plasma membrane and is thought to act as a regulatory protein in receptor-mediated signal transduction, especially in the context of cytoskeletal organization and potentially in the modulation of voltage-dependent calcium channel activity[1][2][7]. The GEM gene undergoes alternative splicing but encodes the same protein through at least two transcript variants[4][5][8]. While GEM is not a direct pharmacological target or established therapeutic protein, changes in its expression have been observed in metabolic, neurological, and musculoskeletal disease contexts, indicating a possible role in disease biology rather than as a current intervention point[4][5][7][8].
None established, since GEM is not a known direct pharmacological target[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GTP binding protein overexpressed in skeletal muscle (GEM).